Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy

Respirology

Volumn 23, Issue 5, 2018, Pages 526-534

  Okumura, Junya ^a   Shindo, Yuichiro ^a   Takahashi, Kunihiko ^a   Sano, Masahiro ^a   Sugino, Yasuteru ^b   Yagi, Tetsuya ^c   Taniguchi, Hiroyuki ^d   Saka, Hideo ^e   Matsui, Shigeyuki ^a   Hasegawa, Yoshinori ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOYOTA MEMORIAL HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

^d TOSEI GENERAL HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

algorithms; antibiotics; community acquired pneumonia; drug resistance, bacterial; pneumonia

Indexed keywords

AZITHROMYCIN; BETA LACTAM; CEFOTAXIME; CEFTRIAXONE; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; SULTAMICILLIN; ANTIINFECTIVE AGENT; CARBON DIOXIDE; SERUM ALBUMIN;

ADULT; AGED; ALBUMIN LEVEL; ANTIBIOTIC THERAPY; ARTERIAL CARBON DIOXIDE TENSION; ARTICLE; BODY TEMPERATURE; BREATHING RATE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONFOUNDING VARIABLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HEMATOCRIT; HUMAN; INFECTIOUS AGENT; LEUKOCYTE COUNT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT; ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; BLOOD; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED INFECTION; METABOLISM; PARTIAL PRESSURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; BODY TEMPERATURE; CARBON DIOXIDE; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HEMATOCRIT; HUMANS; LEUKOCYTE COUNT; MACROLIDES; MALE; PARTIAL PRESSURE; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; RESPIRATORY RATE; SERUM ALBUMIN; TREATMENT OUTCOME;

EID: 85038003452     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.13232     Document Type: Article

References (41)

1. World Health Organization. The top 10 causes of death. [Accessed 28 Sept 2016.] Available from URL: http://www.who.int/mediacentre/factsheets/fs310/en/
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44(Suppl. 2): S27–72.
3. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730–54.
4. Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, Higa F, Takahashi H, Yoshida M, Kohno S et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis. Respirology 2016; 21: 1193–200.
5. Restrepo MI, Chalmers JD, Song Y, Mallow C, Hewlett J, Maldonado F, Yarmus L. Year in review 2016: respiratory infections, acute respiratory distress syndrome, pleural diseases, lung cancer and interventional pulmonology. Respirology 2017; 22: 602–11.
6. Cilloniz C, Civljak R, Nicolini A, Torres A. Polymicrobial community-acquired pneumonia: an emerging entity. Respirology 2016; 21: 65–75.
7. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J et al.; on behalf of the Central Japan Lung Study Group. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2013; 188: 985–95.
8. Self WH, Wunderink RG, Williams DJ, Barrett TW, Baughman AH, Grijalva CG. Comparison of clinical prediction models for resistant bacteria in community-onset pneumonia. Acad. Emerg. Med. 2015; 22: 730–40.
9. Webb BJ, Jones B, Dean NC. Empiric antibiotic selection and risk prediction of drug-resistant pathogens in community-onset pneumonia. Curr. Opin. Infect. Dis. 2016; 29: 167–77.
10. Sibila O, Rodrigo-Troyano A, Shindo Y, Aliberti S, Restrepo MI. Multidrug-resistant pathogens in patients with pneumonia coming from the community. Curr. Opin. Pulm. Med. 2016; 22: 219–26.
11. Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, Tarsia P, Mantero M, Blasi F. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin. Infect. Dis. 2012; 54: 470–8.
12. Loh LC, Quah SY, Khoo SK, Vijayasingham P, Thayaparan T. Addition of macrolide in treating adult hospitalized community-acquired pneumonia. Respirology 2005; 10: 371–7.
13. Emmet O'Brien M, Restrepo MI, Martin-Loeches I. Update on the combination effect of macrolide antibiotics in community-acquired pneumonia. Respir. Investig. 2015; 53: 201–9.
14. Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA 2016; 315: 593–602.
15. Blasi F, Iori I, Bulfoni A, Corrao S, Costantino S, Legnani D. Can CAP guideline adherence improve patient outcome in internal medicine departments? Eur. Respir. J. 2008; 32: 902–10.
16. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 2007; 51: 3977–82.
17. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, Restrepo MI, Rello J. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010; 36: 612–20.
18. Naucler P, Darenberg J, Morfeldt E, Ortqvist A, Henriques Normark B. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013; 68: 571–9.
19. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur. Respir. J. 2009; 33: 153–9.
20. Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sole-Violan J, Rello J, CAPUCI Study Group. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit. Care Med. 2007; 35: 1493–8.
21. Garin N, Genne D, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T et al. Beta-lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern. Med. 2014; 174: 1894–901.
22. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM et al.; CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. N. Engl. J. Med. 2015; 372: 1312–23.
23. Feldman C, Anderson R. New insights into pneumococcal disease. Respirology 2009; 14: 167–79.
24. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I et al.; Central Japan Lung Study Group. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect. Dis. 2015; 15: 1055–65.
25. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996; 22: 707–10.
26. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997; 336: 243–50.
27. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82.
28. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Imaizumi K, Hasegawa Y. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology 2008; 13: 731–5.
29. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin. Infect. Dis. 2008; 47: 375–84.
30. Espana PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, Bilbao A, Quintana JM. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 2006; 174: 1249–56.
31. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, Gabarrus A, Sellares J, Restrepo MI, Anzueto A et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313: 677–86.
32. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratala J et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 2016; 63: e61–e111.
33. Bratzler DW, Ma A, Nsa W. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project. Clin. Infect. Dis. 2008; 47(Suppl. 3): S193–201.
34. Wunderink RG. Community-acquired pneumonia versus healthcare-associated pneumonia. The returning pendulum. Am. J. Respir. Crit. Care Med. 2013; 188: 896–8.
35. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. 1999; 159: 2562–72.
36. Laserna E, Sibila O, Fernandez JF, Maselli DJ, Mortensen EM, Anzueto A, Waterer G, Restrepo MI. Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia. Chest 2014; 145: 1114–20.
37. McEvoy C, Micek ST, Reichley RM, Kan J, Hoban A, Hoffmann J, Shorr AF, Kollef MH. Macrolides are associated with a better survival rate in patients hospitalized with community-acquired but not healthcare-associated pneumonia. Surg. Infect. (Larchmt.) 2014; 15: 283–9.
38. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 2010; 23: 590–615.
39. Steel HC, Theron AJ, Cockeran R, Anderson R, Feldman C. Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm. 2012; 2012: 584262.
40. Nie W, Li B, Xiu Q. Beta-lactam/macrolide dual therapy versus beta-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J. Antimicrob. Chemother. 2014; 69: 1441–6.
41. Shindo Y, Hasegawa Y. Regional differences in antibiotic-resistant pathogens in patients with pneumonia: implications for clinicians. Respirology 2017; 22: 1536–46.